StreetInsider.com News Articles

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 06 Mar 2026 16:05:00 -0500

WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 46,600 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 06 Mar 2026 16:05:00 -0500

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 06 Mar 2026 16:05:00 -0500

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 06 Mar 2026 16:05:00 -0500

Form EFFECT Spyre Therapeutics, Inc.

Thu, 05 Mar 2026 06:04:00 -0500

si-local-file:///var/storage/secattach/20260305/26114551.html

Form EFFECT Spyre Therapeutics, Inc.

Thu, 05 Mar 2026 06:04:00 -0500

si-local-file:///var/storage/secattach/20260305/26114551.html

Form 4 Spyre Therapeutics, Inc. For: Mar 03 Filed by: Burrows Scott L

Tue, 03 Mar 2026 21:33:00 -0500

si-local-file:///var/storage/secattach/20260303/26105645.html

Form 4 Spyre Therapeutics, Inc. For: Mar 03 Filed by: Burrows Scott L

Tue, 03 Mar 2026 21:33:00 -0500

si-local-file:///var/storage/secattach/20260303/26105645.html

Form 4 Spyre Therapeutics, Inc. For: Mar 02 Filed by: Turtle Cameron

Tue, 03 Mar 2026 21:32:00 -0500

si-local-file:///var/storage/secattach/20260303/26105643.html

Form 4 Spyre Therapeutics, Inc. For: Mar 02 Filed by: Turtle Cameron

Tue, 03 Mar 2026 21:32:00 -0500

si-local-file:///var/storage/secattach/20260303/26105643.html

Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L

Tue, 03 Mar 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260303/26102772.html

Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L

Tue, 03 Mar 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260303/26102772.html

Form 144 Spyre Therapeutics, Inc. Filed by: Turtle Cameron

Mon, 02 Mar 2026 16:32:00 -0500

si-local-file:///var/storage/secattach/20260302/26092859.html

Form 144 Spyre Therapeutics, Inc. Filed by: Turtle Cameron

Mon, 02 Mar 2026 16:32:00 -0500

si-local-file:///var/storage/secattach/20260302/26092859.html

Form EFFECT Spyre Therapeutics, Inc.

Mon, 02 Mar 2026 06:09:00 -0500

si-local-file:///var/storage/secattach/20260302/26086250.html

Form EFFECT Spyre Therapeutics, Inc.

Mon, 02 Mar 2026 06:09:00 -0500

si-local-file:///var/storage/secattach/20260302/26086250.html

Form POS AM Spyre Therapeutics, Inc.

Fri, 27 Feb 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260227/26081435.html

Form POS AM Spyre Therapeutics, Inc.

Fri, 27 Feb 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260227/26081435.html

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Tue, 24 Feb 2026 16:05:00 -0500

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

Event: TD Cowen 46th Annual Health Care Conference - Boston
Date: Tuesday, March 3, 2026
Presentation and Fireside Time: 3:10 pm ET

Event: Leerink Global Healthcare Conference – Miami
Date: Monday, March 9, 2026
Fireside Time: 8:40 am ET

Event: Jefferies Biotech on the Beach Summit

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Tue, 24 Feb 2026 16:05:00 -0500

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

Event: TD Cowen 46th Annual Health Care Conference - Boston
Date: Tuesday, March 3, 2026
Presentation and Fireside Time: 3:10 pm ET

Event: Leerink Global Healthcare Conference – Miami
Date: Monday, March 9, 2026
Fireside Time: 8:40 am ET

Event: Jefferies Biotech on the Beach Summit

Spyre (SYRE) PT Raised to $55 at Deutsche Bank

Mon, 23 Feb 2026 07:00:47 -0500
Deutsche Bank analyst David Hoang raised the price target on Spyre (NASDAQ: SYRE) to $55.00 (from $45.00) while maintaining a Buy rating.

Spyre (SYRE) PT Raised to $50 at Wells Fargo

Fri, 20 Feb 2026 07:09:51 -0500
Wells Fargo analyst Yanan Zhu raised the price target on Spyre (NASDAQ: SYRE) to $50.00 (from $40.00) while maintaining a Overweight rating.

Spyre Therapeutics (SYRE) files mixed shelf

Thu, 19 Feb 2026 16:35:52 -0500

Spyre Therapeutics (NASDAQ: SYRE) has filed mixed shelf of:
COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
UNITS

Spyre Therapeutics (SYRE) files mixed shelf

Thu, 19 Feb 2026 16:35:52 -0500

Spyre Therapeutics (NASDAQ: SYRE) has filed mixed shelf of:
COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
UNITS

Form S-3 Spyre Therapeutics, Inc.

Thu, 19 Feb 2026 16:34:00 -0500
si-local-file:///var/storage/secattach/20260219/26030520.html